The CD3-directed monoclonal antibody teplizumab ( Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type…
Med Lett Drugs Ther. 2026 Jun 22; 68(1757):100-1 doi:10.58347/tml.2026.1757c
The CD3-directed monoclonal antibody teplizumab ( Tzield – Provention Bio), which was previously approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old with stage 2 type 1 diabetes, has now been approved for such use in children 1-7 years old.
The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US…
Med Lett Drugs Ther. 2025 Nov 10; 67(1741):e185-6 doi:10.58347/tml.2025.1741g
The FDA has approved Kirsty (Biocon), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of type 1 or type 2 diabetes. Kirsty is the first rapid-acting insulin to become available in the US that has received interchangeability status with NovoLog ; Merilog , another insulin aspart biosimilar, was approved earlier but has not received interchangeability status with NovoLog .
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar…
Med Lett Drugs Ther. 2025 Jun 23; 67(1731):104 doi:10.58347/tml.2025.1731c
The FDA has approved Merilog (Sanofi), a biosimilar to rapid-acting insulin aspart (NovoLog) , for treatment of patients with type 1 or type 2 diabetes. Merilog is the first rapid-acting insulin biosimilar product to become available in the US.
The FDA has approved donislecel-jujn ( Lantidra – CellTrans), an allogeneic pancreatic islet cellular therapy, for use in conjunction with immunosuppression for treatment of adults with type 1 diabetes who…
Med Lett Drugs Ther. 2024 Apr 15; 66(1700):63-4 doi:10.58347/tml.2024.1700d
The FDA has approved donislecel-jujn ( Lantidra – CellTrans), an allogeneic pancreatic islet cellular therapy, for use in conjunction with immunosuppression for treatment of adults with type 1 diabetes who are unable to approach target HbA1c because of current repeated episodes of severe hypoglycemia despite intensive diabetes management and education. Donislecel is the first cell-based treatment to be approved in the US for type 1 diabetes.
Teplizumab-mzwv ( Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1…
Med Lett Drugs Ther. 2023 Jan 9; 65(1667):7-8 doi:10.58347/tml.2023.1667c
Teplizumab-mzwv ( Tzield – Provention Bio), an anti-CD3 monoclonal antibody, has been approved by the FDA to delay the onset of stage 3 type 1 diabetes in patients ≥8 years old who have stage 2 type 1 diabetes. It is the first drug to become available in the US that delays the onset of type 1 diabetes.
Insulin glargine-yfgn ( Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin…
Med Lett Drugs Ther. 2021 Oct 4; 63(1634):159-60
Insulin glargine-yfgn ( Semglee – Viatris), a follow-on insulin glargine product, has now received interchangeability status with the reference product Lantus from the FDA. It is the first biosimilar insulin product to receive this designation in the US. Now a pharmacist can substitute Semglee for Lantus as a lower-cost alternative without permission from the prescriber.
The FDA has approved dasiglucagon ( Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be…
Med Lett Drugs Ther. 2021 Aug 23; 63(1631):132-4
The FDA has approved dasiglucagon ( Zegalogue – Zealand) for subcutaneous (SC) treatment of severe hypoglycemia in patients ≥6 years old with diabetes. Dasiglucagon is the third glucagon product to be marketed in the US that does not require reconstitution before administration; Gvoke , a SC formulation approved for use in patients ≥2 years old, and Baqsimi , an intranasal powder approved for use in patients ≥4 years old, have been available since 2019. Injectable glucagon emergency kits ( GlucaGen HypoKit , and generics) have been available for years, but they require reconstitution of the lyophilized powder immediately before administration.
The FDA has approved Semglee (Mylan), an insulin glargine product similar to Lantus , for treatment of type 1 diabetes in children and adults and type 2 diabetes in adults. Semglee is the second "follow-on"…
Med Lett Drugs Ther. 2021 Jan 25; 63(1616):14-5
The FDA has approved Semglee (Mylan), an insulin glargine product similar to Lantus , for treatment of type 1 diabetes in children and adults and type 2 diabetes in adults. Semglee is the second "follow-on" insulin glargine product to become available in the US; Basaglar , which is also similar to Lantus , was the first. Lantus is a recombinant analog of human insulin that forms microprecipitates in subcutaneous tissue, prolonging its duration of action to a mean of about 24 hours with no pronounced peak effect.
The FDA has approved insulin lispro-aabc ( Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog) , for treatment of type 1 and type 2 diabetes in adults. Fiasp , a faster-acting…
Med Lett Drugs Ther. 2020 Oct 19; 62(1609):162-3
The FDA has approved insulin lispro-aabc ( Lyumjev – Lilly), a faster-acting formulation of insulin lispro (Humalog) , for treatment of type 1 and type 2 diabetes in adults. Fiasp , a faster-acting formulation of insulin aspart (Novolog) , was approved in 2017.
The FDA has approved a new formulation of glucagon ( Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of…
Med Lett Drugs Ther. 2019 Nov 18; 61(1585):186
The FDA has approved a new formulation of glucagon ( Gvoke – Xeris) for subcutaneous treatment of severe hypoglycemia in patients ≥2 years old with diabetes. Conscious patients with symptoms of hypoglycemia can take oral glucose. Glucagon is usually administered by a caregiver to an unresponsive patient. The new formulation is available in a single-use prefilled syringe (Gvoke PFS) and is expected to become available in a single-use auto-injector (Gvoke HypoPen) in 2020. Unlike previously available injectable glucagon products ( Glucagon Emergency Kit , and others), Gvoke does not require reconstitution before administration. A glucagon nasal powder (Baqsimi) that does not require coordination with inhalation was recently approved for use in patients ≥4 years old.
The FDA has approved glucagon nasal powder ( Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become…
Med Lett Drugs Ther. 2019 Sep 23; 61(1581):148-9
The FDA has approved glucagon nasal powder ( Baqsimi – Lilly) for treatment of severe hypoglycemia in patients ≥4 years old with diabetes. Baqsimi is the first noninjectable glucagon formulation to become available in the US. Injectable glucagon emergency kits ( GlucaGen Hypokit , and generic) have been available for years, but they require reconstitution of the lyophilized powder by the caregiver immediately before injection. An injectable glucagon formulation that does not require reconstitution was recently approved by the FDA (Gvoke) and is expected to become available later in 2019; it will be reviewed in a future issue.
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional…
Med Lett Drugs Ther. 2018 Jan 1; 60(1537):6-7
The FDA has approved Fiasp (Novo Nordisk), a new formulation of insulin aspart, to improve glycemic control in adults with diabetes. Fiasp is described by the manufacturer as faster-acting than conventional insulin aspart (Novolog) .
The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin…
Med Lett Drugs Ther. 2017 Jan 2; 59(1511):3-4
The FDA has approved Basaglar (Lilly/Boehringer Ingelheim), a "follow-on" 100 units/mL insulin glargine product similar to Lantus (Sanofi), which recently went off patent. A 300 units/mL formulation of insulin glargine (Toujeo) was approved in 2015.
The FDA has approved the Minimed 670G (Medtronic), a hybrid closed-loop insulin delivery system for use in patients ≥14 years old with type 1 diabetes. The system uses an algorithm to automatically adjust…
Med Lett Drugs Ther. 2016 Nov 21; 58(1508):147-8
The FDA has approved the Minimed 670G (Medtronic), a hybrid closed-loop insulin delivery system for use in patients ≥14 years old with type 1 diabetes. The system uses an algorithm to automatically adjust basal insulin doses based on readings from a continuous glucose monitor (CGM). It fully automates basal insulin delivery in "auto" mode, but is considered a "hybrid" system (not a true "artificial pancreas") because it requires some action by the patient. The 670G system is expected to become available in Spring 2017.
The FDA has approved insulin degludec ( Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the…
Med Lett Drugs Ther. 2015 Dec 7; 57(1483):163-4
The FDA has approved insulin degludec ( Tresiba – Novo Nordisk) for treatment of adults with type 1 or type 2 diabetes. Insulin degludec is the third long-acting human insulin analog to be approved by the FDA; insulin detemir (Levemir) and insulin glargine ( Lantus , Toujeo ) were approved earlier.
The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin ( Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1…
Med Lett Drugs Ther. 2015 Mar 2; 57(1463):34-5
The FDA has approved an inhaled, rapid-acting, dry-powder formulation of recombinant human insulin ( Afrezza – Mannkind/Sanofi) for treatment of adults with type 1 or type 2 diabetes. In patients with type 1 diabetes, the drug must be used in combination with long-acting insulin. Another inhaled, rapid-acting insulin (Exubera) was approved in 2006 for the same indication, but was withdrawn from the market the following year.
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL…
Treat Guidel Med Lett. 2014 Jan; 12(137):1-6
HMG-CoA reductase inhibitors (statins) inhibit the enzyme that catalyzes the rate-limiting step in cholesterol synthesis. The subsequent reduction in hepatic cholesterol leads to increased expression of LDL receptors, which in turn increases uptake and clearance of LDL-C from the blood. Statins also lower very low-density lipoprotein cholesterol (VLDL-C) and triglycerides. Most statins increase high-density lipoprotein cholesterol (HDL-C), but only modestly.
The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial glucose reaches a…
Med Lett Drugs Ther. 2013 Dec 9; 55(1431):97-8
The FDA has approved the MiniMed 530G (Medtronic), an insulin pump used in combination with a continuous glucose monitoring sensor (Enlite) that can stop delivery of insulin when interstitial glucose reaches a prespecified low level. It is the only sensoraugmented insulin pump available in the US with this capability.
A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical…
Med Lett Drugs Ther. 2011 May 2; 53(1363):35-6
A variety of continuous glucose monitoring (CGM) devices have been used in an effort to reduce the hypoglycemia and wide glucose excursions that complicate insulin treatment of diabetes. Since the last Medical Letter issue reviewing such devices, some new devices and some new data on old devices have become available. The devices currently marketed in the US for personal use are listed in Table 1.
An inhaled, dry-powder formulation of rapid-acting human insulin ( Exubera - Pfizer) has been approved by the FDA for treatment of adults with type 1 or type 2 diabetes.
Med Lett Drugs Ther. 2006 Jul 17; 48(1239):57-8
An inhaled, dry-powder formulation of rapid-acting human insulin ( Exubera - Pfizer) has been approved by the FDA for treatment of adults with type 1 or type 2 diabetes.
Insulin detemir ( Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the…
Med Lett Drugs Ther. 2006 Jul 3; 48(1238):54-5
Insulin detemir ( Levemir - Novo Nordisk) is the second long-acting basal insulin analog to be marketed in the US for treatment of both type 1 and type 2 diabetes. Detemir differs from human insulin by the elimination of the amino acid threonine in position B30 and the addition of a 14-carbon fatty acid chain at position B29. Insulin glargine (Lantus) , the first long-acting insulin analog, has been available since 2001 and is usually given once daily.1 NPH insulin is an intermediate-acting basal insulin given twice daily. Basal insulins are usually combined with prandial doses of a rapid-acting insulin.
Insulin glulisine ( Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog) . All three have a more rapid…
Med Lett Drugs Ther. 2006 Apr 24; 48(1233):33-4
Insulin glulisine ( Apidra - Sanofi Aventis) is the third rapid-acting insulin analog to be marketed in the US, following insulin lispro (Humalog) and insulin aspart (Novolog) . All three have a more rapid onset and shorter duration of action than regular human insulin. Rapid-acting insulin analogs are generally taken immediately before meals and are usually combined with a long-acting basal insulin.
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.
Med Lett Drugs Ther. 2006 Feb 27; 48(1229):19-20
Coenzyme Q10, a fat-soluble antioxidant also known as ubidecarenone, ubiquinone and CoQ10, is marketed as a dietary supplement in the US, both as a single ingredient and in various combination products.